

## Technology Advisory Committee D Interests Register

**Topic: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]**

**Publication Date: 26 February 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor David Meads	Committee Member	Direct-Professional	Professor Meads' employer, the University of Leeds, has received funding from BMS for research in an unrelated area.	19/05/2024 04/09/2024	It was agreed that Professor Meads' declaration would not prevent him from participating in discussions on this appraisal.
Dr Matthew Bradley	Committee Member	Direct-Financial	Dr Bradley holds shares in AstraZeneca, the manufacturer of osimertinib.	16/08/2024 15/05/2024	It was agreed that Dr Bradley's declaration would prevent him from participating in discussions on this appraisal.
Dr Elizabeth Toy	Clinical expert	Direct – Financial	<ul style="list-style-type: none"> <li>Dr Toy has been a Principal Investigator and Co-investigator in clinical trials sponsored by AstraZeneca.</li> <li>Dr Toy has participated in an interview with AstraZeneca as preparation for NICE appraisal for which she received an honorarium.</li> </ul>	19/05/2024 04/09/2024	It was agreed that Dr Toy's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> <li>Dr Toy has received speaker fees and honoraria for advisory boards from AstraZeneca.</li> </ul>		
Professor Eric Lim	Clinical expert	Direct - Financial	<ul style="list-style-type: none"> <li>Professor Lim has received fees for speaking engagements, advisory board meetings, and educational programmes from AstraZeneca.</li> <li>Professor Lim has received personal fees from BMS.</li> <li>Professor Lim's hospital, the Royal Brompton Hospital, has received funding from AstraZeneca to develop the My Cancer Companion health app.</li> </ul>	15/11/2023 04/09/2024	It was agreed that Professor Lim's declaration would not prevent him from providing expert advice to the committee.